Bedside Snapshot

Use It For: Stable monomorphic VT or wide-complex tachycardia; stable pre-excited AF (WPW); AF/flutter cardioversion when other agents are not preferred
Adult Dose: Stable VT: 20–50 mg/min IV to an endpoint (max 17 mg/kg), then 1–4 mg/min
Differs from FDA label: load max 1 g; maintenance 2–6 mg/min
Label option: 100 mg IV every 5 min; max 1 g
Pediatric Dose: Expert consultation: 15 mg/kg IV/IO over 30–60 min (PALS 2020–2025; max 15 mg/kg; no pediatric rate cap, adult 50 mg/min applies). No maintenance or infant dose established. Differs from FDA label: not established
Onset / Duration: IV: effect builds during the load, control usually within 30 min / hours (half-life 3–4 hr, longer in renal failure). IM: 10–30 min / hours
Do Not Give / Hold If: Torsades or prolonged QT; complete heart block, or 2nd-degree block or hemiblock without a pacer; SLE; heart failure (AHA: avoid). Pause if BP falls ≥15 mmHg; stop if QRS widens >50%
Watch For: Hypotension (BP every few minutes); QRS widening and AV block (continuous ECG); QT prolongation or torsades (12-lead); with prolonged use, agranulocytosis (CBC)
Reversal / Rescue: No antidote. Stop the infusion; fluids and vasopressors; pacing for block; magnesium and defibrillation for torsades; hemodialysis removes procainamide and NAPA
Must Remember: Stop at the first endpoint: rhythm converts, hypotension, QRS widens >50%, or max dose. Record the baseline QRS first, keep pads on, and never stack it on amiodarone.

Indications

Emergency & Prehospital

Stable, regular, monomorphic wide-complex tachycardia (presumed VT): one IV option, next to amiodarone or sotalol. AHA 2025 Part 9 rates it COR 2b. The 2025 algorithm gives doses for procainamide and amiodarone only. Unstable, or the drugs fail? Synchronized cardioversion.
Stable pre-excited atrial fibrillation (AF) in Wolff-Parkinson-White (WPW) syndrome: in stable patients, the 2023 ACC/AHA AF guideline offers IV procainamide or ibutilide (Class 1) as an alternative to elective cardioversion. Part 9 of the 2025 AHA Guidelines for CPR and ECC files pre-excited AF/flutter under wide-complex. Go to synchronized cardioversion (COR 1) if the patient is unstable, or if drugs fail or are contraindicated. For adults with wide-complex tachycardia in general (COR 2b, B-R), IV amiodarone, procainamide or sotalol may be considered. Pre-excited AF is not named. Here's the catch: Part 9 AF/flutter recommendation 3 (COR 3: Harm, C-LD) says digoxin, non-dihydropyridine calcium channel blockers, beta-blockers and IV amiodarone should not be given in preexcitation AF/flutter, because they may increase the ventricular response and cause VF. Procainamide use for this indication is off-label.

ED / ICU / Transport

Life-threatening ventricular arrhythmias, such as sustained VT: the indication on the FDA label
Pharmacologic cardioversion of AF or atrial flutter: a fallback when other IV agents are contraindicated or not preferred. Ibutilide works better. Check AF duration and anticoagulation first (thromboembolism risk, see Precautions) (off-label)
Stable AF in pregnancy with a structurally normal heart: may be considered for cardioversion with specialist input (off-label)
Pediatric SVT with cardiopulmonary compromise: when vagal maneuvers, adenosine and cardioversion fail and no expert is available. The 2025 AHA Guidelines, Part 8, give COR 2b (C-LD) and no dose (off-label).

Other Uses

Arrhythmias during surgery or anesthesia: labeled IM use; now uncommon

Not for Arrest or Torsades: Not here. In VF or pulseless VT, the infusion is slow and its benefit is uncertain (2025 AHA Guidelines for CPR and ECC, Part 9, COR 2b, C-LD). Defibrillate. Consider amiodarone or lidocaine. Torsades de pointes is a labeled contraindication. Reach for magnesium, and defibrillate if pulseless.

Dosing & Administration

AHA 2025 and the FDA label set the doses below. Where they differ, the AHA option leads and the label is noted.

Available Forms

Vial, 100 mg/mL: 10 mL multiple-dose vial (1 g)
Vial, 500 mg/mL: 2 mL multiple-dose vial (1 g)
Excipients: sodium metabisulfite (a sulfite) and methylparaben

High-Alert Medication: Both vials hold 1 g, so the vial you pick decides the dose. Draw from the 500 mg/mL vial when you meant the 100 mg/mL vial, and it's a 5-fold overdose. Two more traps: pushing faster than 50 mg/min, and losing count of the running total. Independently double-check strength, concentration, rate, and the cumulative mg and mg/kg.

Adult Dosing

Indication	Dose & Route	Repeat / Max	Notes
Stable monomorphic VT / wide-complex tachycardia (AHA)	20–50 mg/min IV infusion	Stop when the arrhythmia is suppressed, hypotension develops, QRS widens >50%, or max 17 mg/kg	High-alert Then 1–4 mg/min. Avoid if prolonged QT or heart failure. Differs from FDA label: label max 1 g total load (17 mg/kg is about 1.2 g at 70 kg).
Ventricular arrhythmia, label incremental load	100 mg IV every 5 min, no faster than 50 mg/min	After 500 mg, wait ≥10 min before more; max 1 g total load	High-alert Dilute either vial strength before pushing; same stop rules.
Ventricular arrhythmia, label loading infusion	500–600 mg IV over 25–30 min (20 mg/mL at 1 mL/min = 20 mg/min)	More than 600 mg is rarely needed; max 1 g total load	High-alert
Pre-excited AF (stable) or AF cardioversion (off-label)	1 g IV over 30 min, then 2 mg/min for 1 hr	Max 1 g load; same QRS and BP stop rules	High-alert Not after amiodarone or ibutilide (stacked QT prolongation). Check AF duration and anticoagulation first.
Maintenance infusion	1–4 mg/min IV (AHA)	Differs from FDA label: label maintenance 2–6 mg/min; no fixed max: titrate to rhythm, QRS, BP and levels	High-alert Expect lower needs with renal impairment, heart failure or age over 50.
Less urgent arrhythmia, unable to take PO (label)	50 mg/kg/day IM, divided every 3–6 hr; surgery or anesthesia: 100–500 mg IM	Reassess after 3 injections (age, renal function, response, levels)	Oral procainamide is no longer marketed in the US.

Pediatric Dosing

Specialist Use: Pediatric safety is not established in labeling. PALS 2025 has no procainamide dose at all. The 15 mg/kg load comes from the PALS 2020–2025 algorithm. Expert consultation first. Differs from FDA label: the label gives no pediatric dose.

Indication	Dose (per kg) & Route	Max Single / Max Total	Notes
Refractory SVT or wide-complex tachycardia (expert consultation)	15 mg/kg IV/IO over 30–60 min (PALS 2020–2025 algorithm)	Max 15 mg/kg load; no pediatric rate cap is stated (adult 50 mg/min is the upper limit)	High-alert Stop if QRS widens >50% or hypotension. PALS says amiodarone and procainamide are not typically given together. The 2025 PALS algorithm gives no dose.
Maintenance and other pediatric regimens	Not established: specialist use only	—	Incremental, infusion and IM pediatric doses were removed: no guideline or label states them. Discuss with pediatric cardiology.
Neonates	Not established: specialist use only	—	Pediatric cardiology directs dosing.

See weight-based dosing.

Continuous Infusion

Setting	Example Concentration	Start	Titrate	Usual Range / Max
Adult loading infusion (label)	20 mg/mL: 1 g diluted to 50 mL with D5W (example, institution-specific)	1 mL/min (20 mg/min)	Stop at an endpoint	25–30 min (500–600 mg); max 1 g
Adult maintenance	4 mg/mL: 1 g in 250 mL D5W (example, institution-specific)	1 mg/min = 15 mL/hr	By rhythm, QRS, BP, renal function	1–4 mg/min (AHA) = 15–60 mL/hr; label 2–6 mg/min

Preparation & Administration

Dilution: dilute either concentration (100 mg/mL or 500 mg/mL) before IV injection. That keeps the rate at ≤50 mg/min. The 500 mg/mL vial is never pushed undiluted. Label infusions are mixed in D5W.
Push rate: adults no faster than 50 mg/min. Children: the PALS load runs over 30–60 min; no pediatric rate cap is stated, so the adult 50 mg/min maximum is the upper limit.
Position and monitoring: keep the patient supine with continuous ECG and frequent BP checks; defibrillator pads on.
Pump: pump both the loading and the maintenance infusions. Transient high levels cause hypotension, so watch the flow.
Appearance: a slight yellow color is acceptable. Discard solution darker than light amber.

Renal and hepatic considerations: see Special Populations.

Contraindications & Precautions

Contraindications

Complete heart block (risk of asystole); 2nd-degree AV block or hemiblock unless a pacemaker controls the rate
Torsades de pointes; avoid with a prolonged QT interval
Established systemic lupus erythematosus (SLE)
Hypersensitivity to procainamide, including allergic dermatitis, asthma or anaphylaxis on exposure
Heart failure (relative): AHA 2025 says avoid it if QT is prolonged or in CHF. The label asks for caution in heart failure, acute ischemia or cardiomyopathy. Even slight myocardial depression can drop output from a damaged heart
Myasthenia gravis (relative): weakness worsens unless anticholinesterase therapy is adjusted

Precautions

Atrial flutter or AF without pre-excitation: Control AV conduction, or cardiovert first, because it can speed up.
AF or flutter conversion and embolism: converting to sinus rhythm by drug or by shock can dislodge atrial thrombi, and a stroke can follow. AF or flutter lasting more than 48 hr, or of unknown duration, without anticoagulation carries thromboembolic risk. AHA advises expert consultation before converting, even under 48 hr, unless cardioversion is emergent.
First-degree AV block: reduce the dose.
Known or suspected Brugada syndrome: avoid. Blocking sodium channels can unmask a type 1 Brugada pattern, and that can trigger ventricular arrhythmias. The drug is used as a diagnostic challenge only in a monitored electrophysiology setting. BrugadaDrugs.org names procainamide among the drugs to avoid.
Hypersensitivity: stay close after the first dose. In patients sensitive to procaine or other ester local anesthetics, cross-sensitivity is unlikely.
Digoxin toxicity: asystole or VF is the risk. Use only after other measures fail.
Renal impairment or age over 50: both the drug and its metabolite build up, so lower doses suffice.
Hypokalemia, hypoxia, acid-base disorders: correct these first.
Sulfite sensitivity; marrow failure or cytopenia: use with caution.

Hold / Reassess If

BP falls ≥15 mmHg: pause the infusion; symptomatic hypotension: stop and treat
QRS widens >25%: suspect excess drug; QRS widens >50%: stop
Marked QT prolongation or new 2nd- or 3rd-degree AV block: stop
New or worsening 1st-degree AV block: reduce the dose and reassess; stop if the conduction disturbance persists
Ventricular rate slows with no visible AV conduction: stop (possible hidden complete heart block)

FDA Boxed Warning: (1) A positive antinuclear antibody (ANA) test is common after prolonged use, with or without a lupus-like syndrome. If the ANA turns positive, reassess benefit against risk. (2) Mortality: in the Cardiac Arrhythmia Suppression Trial (CAST), encainide and flecainide raised mortality. Save procainamide for life-threatening ventricular arrhythmias. (3) Blood dyscrasias: agranulocytosis and marrow depression in about 0.5%. Agranulocytosis is fatal in 20–25% of reported cases, and most of it shows up in the first 12 weeks. Run a CBC weekly for 3 months. Some generic labels box just the ANA warning.

Adverse Effects & Toxicity

Common

Hypotension: clinically significant in 5–12% with IV use for AF. A fast infusion makes it more likely, through transient high levels
QRS widening; PR and QT prolongation
Rash, flushing, pruritus, urticaria
Nausea, vomiting, bitter taste, diarrhea (3–4% on oral therapy)
Dizziness, weakness; rarely psychosis
Positive ANA in at least 50% on long-term therapy

Serious / Life-Threatening

Effect	Recognition	Management
Hypotension, shock	Falling BP during the load; transient high levels cause vasodilation	Pause or stop; fluids; phenylephrine or norepinephrine
Proarrhythmia: torsades, VT, VF	QRS and QT lengthening, R-on-T beats, faster or polymorphic VT	Stop; magnesium for torsades; defibrillate if pulseless
AV block, asystole	PR prolongation, dropped beats, slowing without AV conduction	Stop; pacing
Agranulocytosis, other cytopenias	Fever, sore throat, mouth sores, bruising; mostly in the first 12 weeks; 20–25% mortality in reported agranulocytosis	Stop; CBC; counts usually recover within 1 month
Lupus-like syndrome	Arthralgia, pleuritic or abdominal pain, pericarditis, fever; up to 30% on long-term oral therapy	Stop; corticosteroids if symptoms persist
Hepatotoxicity; hypersensitivity	Rising transaminases (liver-failure deaths reported); angioedema, bronchospasm	Stop; liver tests; epinephrine for anaphylaxis

Overdose & Toxicity Management

Signs: progressive QRS widening, PR and QT prolongation, AV block, VT or VF; hypotension; CNS and respiratory depression, tremor.
Levels: procainamide above 10 mcg/mL is increasingly toxic. Toxicity is common above 15 mcg/mL.
Treat: stop the drug; vasopressors; pacing; mechanical cardiorespiratory support if refractory. Hypertonic sodium bicarbonate is used by extrapolation from other class Ia poisonings. Get toxicology input.
Removal and antidote: no specific antidote. Hemodialysis removes procainamide and NAPA; peritoneal dialysis does not. Poison control: 1-800-222-1222.

Monitoring

Parameter	When / How Often	Target / Act If
Clinical: ECG	Continuous during load and infusion; baseline 12-lead QRS and QTc	QRS >25% wider: suspect excess drug, reassess; >50% wider, marked QT prolongation or new 2nd- or 3rd-degree AV block: stop; new 1st-degree block: reduce the dose
Clinical: BP	Supine; every few minutes during the load	Fall ≥15 mmHg: pause; symptomatic hypotension: stop, fluids, vasopressor
Clinical: rhythm response	Continuous	Suppressed: end the load; rate slows without AV conduction: stop
Laboratory: potassium, magnesium	Before the load; repeat during prolonged infusion	Correct hypokalemia and hypomagnesemia (torsades risk)
Laboratory: creatinine	Baseline; repeat during prolonged infusion	Reduced clearance: lower maintenance rate; check levels
Drug levels: procainamide and NAPA	If available, on prolonged infusions or with renal impairment	Procainamide 3–10 mcg/mL (label; AHFS 4–10); procainamide + NAPA 5–30 mcg/mL. Toxicity rises above 10 and is common above 15: judge the level against ECG, BP and response. Some patients with sustained VT need higher levels (up to 15–20 mcg/mL) under close monitoring
Laboratory: CBC with differential and platelets	Weekly for the first 3 months of continued therapy; at once for fever, sore throat or bruising	Any cytopenia: stop procainamide
Laboratory: ANA	Before and periodically during prolonged therapy	Rising titer or lupus symptoms: reassess or stop

Interactions & Compatibility

Clinically Significant Interactions

Drug / Class	Effect	What To Do
Amiodarone	Additive QT prolongation; raises procainamide and NAPA levels	Avoid procainamide after amiodarone; if both are needed, cut procainamide by 20–33% and monitor
Sotalol, ibutilide, other QT-prolonging drugs (e.g., macrolides, fluoroquinolones, antipsychotics, ondansetron, methadone)	Torsades	Use one antiarrhythmic; expert input before a second; ECG and K⁺/Mg²⁺
Quinidine, disopyramide (class Ia)	Additive conduction delay, negative inotropy, hypotension	Reserve for refractory arrhythmia with close monitoring
Cimetidine, trimethoprim, ranitidine (withdrawn from the US market)	Less renal secretion: higher procainamide and NAPA levels	Monitor levels and ECG; famotidine does not interact
Anticholinergics (e.g., atropine)	Additive vagolytic effect on AV-node conduction: faster ventricular rate in flutter or AF	Control AV conduction first; continuous ECG
Succinylcholine, nondepolarizing neuromuscular blockers	Potentiated block (less acetylcholine release)	Smaller doses may be needed; monitor recovery
Antihypertensives, IV vasodilators	Additive hypotension	Close BP monitoring

IV Compatibility

Diluents: the label uses D5W; 0.9% sodium chloride is compatible (2–4 mg/mL stable 24 hr at room temperature). D5W stability varies by preparation; D5W with 0.9% sodium chloride is incompatible.
Y-site incompatible: milrinone; diltiazem variable. Admixture incompatible: esmolol, milrinone.
Y-site compatible (selected): amiodarone, heparin, potassium chloride, metoprolol, vasopressin, dexmedetomidine.
Verify with an institutional compatibility resource.

Special Populations

Pediatrics: labeling does not establish safety or effectiveness. Use with expert consultation. See the Pediatric Dosing table.
Neonates: not established; specialist use only.
Pregnancy: no animal reproduction studies exist. The FDA label says placental transfer is unknown. The AHFS monograph reports that procainamide and NAPA cross the placenta. Give only if clearly needed (label). The 2023 AF guideline lists IV procainamide as an option for stable AF, including pre-excited AF, in pregnancy. Avoid the first trimester if possible. Electrical cardioversion is safe for mother and fetus.
Lactation: procainamide and NAPA pass into breast milk, and the infant absorbs them. Stop breastfeeding or the drug, weighing its importance to the mother.
Older Adults: renal excretion of procainamide and NAPA falls about 25% by age 50 and 50% by age 75. That happens independent of creatinine clearance. Start at the low end and expect lower maintenance needs.
Renal Impairment: procainamide and NAPA accumulate. Reduce the maintenance rate and follow levels. The label gives no creatinine-clearance table. Hemodialysis removes both. Peritoneal dialysis does not.
Hepatic Impairment: no specific dosage recommendations; titrate to ECG and BP.
Obesity / Dosing Weight: the AHA 17 mg/kg maximum does not name a dosing weight. The label caps the load at 1 g, whatever the weight. Differs from FDA label: 17 mg/kg is about 1.2 g at 70 kg, above that 1 g cap.
Acetylator Status: fast acetylators convert more drug to NAPA (class III, QT-prolonging). Slow acetylators may develop the lupus-like syndrome more often.
Myasthenia Gravis or SLE: myasthenia may worsen. SLE is a contraindication.

Field & Transport Considerations

Scope: Paramedic and critical-care transport per local protocol. The label limits parenteral use to settings with monitoring and resuscitation capability. It varies by state and agency protocol.
Storage & Stability: 20–25°C (68–77°F). A slight yellowing is acceptable, but darker than light amber is not. Avoid vehicle heat extremes.
Carried Concentration: confirm 100 mg/mL (10 mL) versus 500 mg/mL (2 mL) before you draw up. Both vials hold 1 g.
Infusions in Transport: pump only; keep a running total in mg and mg/kg; BP every few minutes during the load; pads on and pacing available.
Handoff Essentials: start time, regimen, total mg and mg/kg, current rate, baseline and current QRS and QTc, BP response, and which endpoint stopped the load.

Clinical Pearls

Exam Discriminator: Pre-Excited AF: Irregular, very fast, broad QRS complexes that keep changing shape point to AF down an accessory pathway. Unstable, or drugs failing? Cardiovert. Stable? Procainamide or ibutilide (2023 AF guideline Class 1), or elective cardioversion. Adenosine, diltiazem, verapamil, beta-blockers, digoxin and IV amiodarone can trigger VF.

Stable VT Options in AHA 2025: Amiodarone, procainamide and sotalol are equal 2b options.

Procainamide: hypotension risk. Infuse no faster than 50 mg/min
Amiodarone: slower onset. It was not more effective than procainamide
Sotalol: similar efficacy to procainamide, with less hypotension

PROCAMIO Trial: In tolerated wide-QRS tachycardia, procainamide caused fewer major cardiac adverse events than amiodarone: 9% vs 41%. More episodes ended within 40 minutes: 67% vs 38%. Small trial, though: 62 analyzed, open-label. Dosing was procainamide 10 mg/kg over 20 min vs amiodarone 5 mg/kg over 20 min.

One Antiarrhythmic at a Time: Stacking procainamide on amiodarone, sotalol or ibutilide piles up QT prolongation and proarrhythmia. If the first drug fails, cardiovert or get expert input before adding a second.

Atrial Flutter Paradox: In flutter without pre-excitation, slowing the atrial rate and adding the vagolytic effect can give you 1:1 conduction. The ventricular rate jumps suddenly. Control AV conduction first.

Watch the QRS, Not Just the Milligrams: QRS widening is the toxicity signal and the stop rule, both at once. Record a baseline QRS before the first milligram. Only then does the 50% threshold mean anything.

Pharmacology

Mechanism of Action

Na⁺ channel block (class Ia): slows conduction in atria, His-Purkinje fibers and ventricles, so the QRS widens. It suppresses re-entry and ectopic automaticity.
Longer refractory period: mostly in atrial and accessory-pathway tissue. That terminates pre-excited AF.
NAPA (class III K⁺ block): prolongs repolarization, so the QT lengthens and the torsades risk rises.
Vagolytic effect: may speed AV-node conduction, giving a faster ventricular rate in flutter.
Vasodilation at high levels, mild negative inotropy: Expect hypotension and worse output in a damaged ventricle.

Pharmacokinetics

Route	Onset	Peak	Duration
IV	Minutes; control usually within 30 min	End of the load	Hours; longer in renal impairment or older age
IM	10–30 min	15–60 min	Hours

Half-life: procainamide 3–4 hr (range 2.5–4.7); NAPA 6–7 hr; longer with renal impairment and age.
Metabolism: hepatic acetylation to active NAPA: 16–21% of a dose in slow acetylators, 24–33% in fast acetylators.
Elimination: renal (glomerular filtration and tubular secretion): 30–60% as unchanged procainamide, 6–52% as NAPA.
Protein binding / Vd: 15–20%; about 2 L/kg.

Names & Classification

Generic Name: Procainamide hydrochloride
Brand Names: Pronestyl and Procanbid (both discontinued); generic injection only in the US
Pharmacologic Class: Class Ia antiarrhythmic (sodium channel blocker); active metabolite NAPA has class III activity
Therapeutic Class: Antiarrhythmic
Controlled Substance: Not controlled
ISMP High-Alert: Yes: ISMP high-alert medication (antiarrhythmics, IV)
Look-Alike / Sound-Alike: None on the ISMP List of Confused Drug Names; the 100 mg/mL and 500 mg/mL vials are a concentration trap

References

Nexus Pharmaceuticals, LLC. (2024). Procainamide hydrochloride injection, USP (100 mg/mL and 500 mg/mL): Prescribing information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d58751df-cd8b-45a6-8a32-af19e747e23a
Wigginton, J. G., et al. (2025). Part 9: Adult advanced life support: 2025 American Heart Association Guidelines for CPR and ECC. Circulation, 152(16 Suppl 2), S538–S577. https://doi.org/10.1161/CIR.0000000000001376
American Heart Association. (2025). Adult tachyarrhythmia with a pulse algorithm. 2025 AHA Guidelines for CPR and ECC. https://cpr.heart.org/-/media/CPR-Files/CPR-Guidelines-Files/2025-Algorithms/Algorithm-ACLS-Tachycardia-250514.pdf?sc_lang=en
Lasa, J. J., et al. (2025). Part 8: Pediatric advanced life support: 2025 AHA and AAP Guidelines for CPR and ECC. Circulation, 152(16 Suppl 2), S479–S537. https://doi.org/10.1161/CIR.0000000000001368
Joglar, J. A., et al. (2024). 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation. Circulation, 149(1), e1–e156. https://doi.org/10.1161/CIR.0000000000001193
Ortiz, M., et al. (2017). Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: The PROCAMIO study (landmark trial). European Heart Journal, 38(17), 1329–1335. https://doi.org/10.1093/eurheartj/ehw230
American Society of Health-System Pharmacists. (2025). Procainamide (AHFS DI Essentials monograph). Drugs.com. https://www.drugs.com/monograph/procainamide.html
Pritchard, B., & Thompson, H. (2023). Procainamide. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK557788/
PALS Pediatric Tachycardia With a Pulse Algorithm, 2020 AHA guidelines (2020–2025 version, reproduced at acls-algorithms.com; procainamide 15 mg/kg IV over 30–60 minutes). https://acls-algorithms.com/wp-content/uploads/2022/08/2020-2025-PALS-Tachycardia-with-pulse-algorithm.pdf
Institute for Safe Medication Practices. (2024). ISMP List of High-Alert Medications in Acute Care Settings. https://www.ismp.org/recommendations/high-alert-medications-acute-list
BrugadaDrugs.org. (accessed 2026). Drugs to be avoided (procainamide listed). https://www.brugadadrugs.org/avoid/

Last updated October 2026 Spotted something wrong? Report an error and include the page URL.

Medical Disclaimer

For Educational Purposes Only: This content is intended for educational reference and should not be used for clinical decision-making.
Not a Substitute for Professional Judgment: Always consult your local protocols, institutional guidelines, and supervising physicians.
Verify Before Acting: Users are responsible for verifying information through authoritative sources before any clinical application.

AI Assistance Notice

AI was used to assist in organizing, paraphrasing, and formatting this information.